SPEARHEAD-1 Trial Design:

A Phase 2, Single-Arm, Open-Label Clinical Trial of ADP-A2M4 SPEAR T-Cells in Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Dejka Araujo[1], Jean-Yves Blay[2], Sandra Strauss[3], Claudia Valverde[4], Erin Van Winkle[5], Malini Iyengar[5]

[1]MD Anderson Cancer Center, Houston, TX, USA, [2]Leon Berard, Lyon, France, [3]University College London Hospitals, London, UK, [4]Vall D'Hebron University Hospital, Barcelona, Spain, [5]Adaptimmune, Philadelphia, PA, USA

An electronic copy of the poster can be viewed by scanning the QR code



Background

- ADP-A2M4 SPEAR T-cells target MAGE-A4⁺ tumors (**Figure 1**)
- MAGE-A4 is highly expressed in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) in the context of HLA-A*02 (**Figure 2**)

Figure 1. SPEAR T-cells



Figure 2. MAGE-A4 expression (IHC analysis)



SPEAR T-cell mechanism of action video can be viewed by scanning the QR code

Full trial details from ClinicalTrials.gov can be viewed by scanning the QR code

Soft tissue sarcomas

- >50 subtypes, including liposarcoma and synovial sarcoma
- Prognosis in advanced disease remains unfavorable

Synovial Sarcoma

- ~800–1000 new cases/year in the United States
- Often occurs in patients aged <40 years
- High metastatic potential

MRCLS

- ~750 new cases/year in the United States
- Typically presents at 35–55 years of age
- One-third MRCLS become metastatic





SPEARHEAD-1 trial (NCT04044768)

- Recruiting 60 patients from North America and Europe
- Advanced synovial sarcoma or MRCLS, prior chemotherapy, HLA-A*02 and MAGE-A4 positive

Trial Details

- We are currently recruiting trial participants
- Study design and engineered T-cell pathway are shown below (**Figure 3** and **Figure 4**)

Figure 3. SPEARHEAD-1 trial design



[a]Patient is hospitalized for T-cell infusion and discharged at the discretion of the Investigator

Figure 4. Patient cell journey



Abbreviations

HLA, human leukocyte antigen; IHC, immunohistochemistry; MAGE-A4, melanoma-associated antigen-A4; MRCLS, myxoid/round cell liposarcoma; PD, progressive disease; RECIST, response evaluation criteria in solid tumors; SPEAR, specific peptide enhanced affinity receptor; TCR, T-cell receptor

Principal investigator details:

- Dejka M. Araujo, MD
- (+1) 713-792-3626
- daraujo@mdanderson.org

SITC 34th Annual Meeting, November 6–10, 2019